DE4000397A1 - Lipidselektive antioxidantien sowie deren herstellung und verwendung - Google Patents

Lipidselektive antioxidantien sowie deren herstellung und verwendung

Info

Publication number
DE4000397A1
DE4000397A1 DE4000397A DE4000397A DE4000397A1 DE 4000397 A1 DE4000397 A1 DE 4000397A1 DE 4000397 A DE4000397 A DE 4000397A DE 4000397 A DE4000397 A DE 4000397A DE 4000397 A1 DE4000397 A1 DE 4000397A1
Authority
DE
Germany
Prior art keywords
radical
compounds
formula
acid
lower alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE4000397A
Other languages
German (de)
English (en)
Inventor
Klaus Ulrich Dr Weithmann
Guenther Dr Wess
Dirk Dr Seiffge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst AG filed Critical Hoechst AG
Priority to DE4000397A priority Critical patent/DE4000397A1/de
Priority to EP90125641A priority patent/EP0436936A2/de
Priority to NZ236709A priority patent/NZ236709A/xx
Priority to HU9128A priority patent/HU210905B/hu
Priority to US07/638,321 priority patent/US5318987A/en
Priority to NO91910075A priority patent/NO910075L/no
Priority to PT96438A priority patent/PT96438B/pt
Priority to CA002033755A priority patent/CA2033755A1/en
Priority to IE005991A priority patent/IE910059A1/en
Priority to KR1019910000149A priority patent/KR910014365A/ko
Priority to JP3059813A priority patent/JPH04331284A/ja
Priority to ZA91132A priority patent/ZA91132B/xx
Priority to AU69217/91A priority patent/AU652928B2/en
Publication of DE4000397A1 publication Critical patent/DE4000397A1/de
Priority to US08/212,863 priority patent/US5508275A/en
Priority to AU61892/94A priority patent/AU660248B2/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/70—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with two hydrocarbon radicals attached in position 2 and elements other than carbon and hydrogen in position 6
    • C07D311/72—3,4-Dihydro derivatives having in position 2 at least one methyl radical and in position 6 one oxygen atom, e.g. tocopherols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/66—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/08—Six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J33/00—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J33/002—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Anti-Oxidant Or Stabilizer Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyrane Compounds (AREA)
DE4000397A 1990-01-09 1990-01-09 Lipidselektive antioxidantien sowie deren herstellung und verwendung Withdrawn DE4000397A1 (de)

Priority Applications (15)

Application Number Priority Date Filing Date Title
DE4000397A DE4000397A1 (de) 1990-01-09 1990-01-09 Lipidselektive antioxidantien sowie deren herstellung und verwendung
EP90125641A EP0436936A2 (de) 1990-01-09 1990-12-28 Lipidselektive Antioxidantien sowie deren Herstellung und Verwendung
NZ236709A NZ236709A (en) 1990-01-09 1991-01-07 Lipid selective antioxidants and their use in foods and pharmaceutical compositions
HU9128A HU210905B (en) 1990-01-09 1991-01-07 Process for producing and utilizing lipide-selective antioxidants and process for producing pharmaceutical compositions
US07/638,321 US5318987A (en) 1990-01-09 1991-01-07 Lipid-selective antioxidants and their preparation and use
CA002033755A CA2033755A1 (en) 1990-01-09 1991-01-08 Lipid-selective antioxidants and their preparation and use
PT96438A PT96438B (pt) 1990-01-09 1991-01-08 Processo para preparacao de anti-oxidante lipideo-selectivos e de composicoes farmaceuticas que os contem
NO91910075A NO910075L (no) 1990-01-09 1991-01-08 Lipidselektive antioksydanter samt deres fremstilling og anvendelse.
IE005991A IE910059A1 (en) 1990-01-09 1991-01-08 Lipid-selective antioxidants and their preparation and use
KR1019910000149A KR910014365A (ko) 1990-01-09 1991-01-08 지질-선택성 산화방지제, 이의 제조방법 및 용도
JP3059813A JPH04331284A (ja) 1990-01-09 1991-01-08 脂質選択性抗酸化剤およびその製法
ZA91132A ZA91132B (en) 1990-01-09 1991-01-08 Lipid-selective antioxidants and their preparation and use
AU69217/91A AU652928B2 (en) 1990-01-09 1991-01-08 Lipid-selective antioxidants and their preparation and use
US08/212,863 US5508275A (en) 1990-01-09 1994-03-15 Lipid-selective antioxidants and their preparation and use
AU61892/94A AU660248B2 (en) 1990-01-09 1994-05-04 Lipid-selective antioxidants and their preparation and use

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4000397A DE4000397A1 (de) 1990-01-09 1990-01-09 Lipidselektive antioxidantien sowie deren herstellung und verwendung

Publications (1)

Publication Number Publication Date
DE4000397A1 true DE4000397A1 (de) 1991-07-11

Family

ID=6397761

Family Applications (1)

Application Number Title Priority Date Filing Date
DE4000397A Withdrawn DE4000397A1 (de) 1990-01-09 1990-01-09 Lipidselektive antioxidantien sowie deren herstellung und verwendung

Country Status (13)

Country Link
US (2) US5318987A (enExample)
EP (1) EP0436936A2 (enExample)
JP (1) JPH04331284A (enExample)
KR (1) KR910014365A (enExample)
AU (2) AU652928B2 (enExample)
CA (1) CA2033755A1 (enExample)
DE (1) DE4000397A1 (enExample)
HU (1) HU210905B (enExample)
IE (1) IE910059A1 (enExample)
NO (1) NO910075L (enExample)
NZ (1) NZ236709A (enExample)
PT (1) PT96438B (enExample)
ZA (1) ZA91132B (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996038464A1 (en) * 1995-05-30 1996-12-05 Lehigh University Antimicrobial sterol conjugates
DE10028142A1 (de) * 2000-06-07 2001-12-20 Boehme Chem Fab Kg Chromgerbverfahren
DE102013226423A1 (de) 2013-12-18 2015-06-18 Henkel Ag & Co. Kgaa Haarbehandlungsmittel mit spezieller Konditioniermittelkombination
CN110407805A (zh) * 2019-07-09 2019-11-05 江苏第二师范学院（江苏省教育科学研究院） 硫辛酸醛类衍生物及其制备方法、应用

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ245504A (en) * 1991-12-20 1995-08-28 Hoechst Ag Bile acid derivatives containing an ethylenically unsaturated grouping
HU215912B (hu) * 1992-04-07 1999-03-29 Merrell Dow Pharmaceuticals Inc. Eljárás 3,4-dihidro-2H-1-benzopiránok hidrazidszármazékai, és ezeket tartalmazó gyógyszerkészítmények előállítására
DE4312034A1 (de) * 1993-04-13 1994-10-20 Hesch Rolf Dieter Prof Dr Med Neuartige Androgene und Anabolika
DE4338316A1 (de) * 1993-11-10 1995-05-11 Jenapharm Gmbh Neue Steroide mit radikophilen Substituenten, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
ES2072223B1 (es) * 1993-11-25 1996-03-16 Lipotec Sa Liposomas encapsulando doxorubicina.
DE4439477C2 (de) * 1994-11-08 1999-10-21 Asta Medica Ag Verwendung von R,S-(+/-)-alpha-Liponsäure, R-(+)-alpha-Liponäure, S-(-)-alpha-Liponsäure in reduzierter oder oxidierter Form oder der Metabolite sowie deren Salze, Ester, Amide zur Behandlung der diabetischen Mikroangiopathie
US5922335A (en) * 1995-05-15 1999-07-13 Avon Products, Inc. Uses for ascorbyl-phosphoryl-cholesterol in topical compositions
US5951990A (en) * 1995-05-15 1999-09-14 Avon Products, Inc. Ascorbyl-phosphoryl-cholesterol
US6162450A (en) * 1995-05-15 2000-12-19 Avon Products, Inc. Uses of ascorbyl-phosphoryl-cholesterol and compositions for practicing same
US5607968A (en) * 1995-06-07 1997-03-04 Avon Products, Inc. Topical alkyl-2-O-L-ascorbyl-phosphates
DE69605556T2 (de) * 1996-05-14 2000-06-15 Avon Products, Inc. Ascorbyl-phosphorylcholesterol
AU740577B2 (en) * 1996-05-14 2001-11-08 Avon Products Inc. Ascorbyl-phosphoryl-cholesterol
JP3588734B2 (ja) * 1996-07-26 2004-11-17 コニカミノルタホールディングス株式会社 電子写真感光体
DE19633560A1 (de) * 1996-08-21 1998-02-26 Basf Ag Chromanyl-ascorbinsäurederivate, deren Herstellung und Verwendung
IL123887A0 (en) 1997-04-02 1998-10-30 Sankyo Co Dithiolan derivatives their use and pharmaceutical compositions containing the same
JPH10298174A (ja) * 1997-04-30 1998-11-10 Showa Denko Kk アスコルビン酸誘導体及びそれを含有するビタミンｃ剤
US6127409A (en) * 1997-04-30 2000-10-03 Showa Denko Kabushiki Kaisha Ascorbic acid derivative and vitamin C preparation containing the same
US5990153A (en) * 1997-05-05 1999-11-23 Wood; John G. Ultrasonicated α-lipoic acid solutions for attenuating microvascular injury
US6090842A (en) * 1998-03-10 2000-07-18 The Regents Of The University Of California Lipoic acid analogs
DK1105096T3 (da) 1998-08-19 2004-03-08 Skyepharma Canada Inc Injicerbare vandige propofoldispersioner
DE19915576A1 (de) 1999-03-30 2000-10-05 Jenapharm Gmbh Equileninderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
IT1311922B1 (it) * 1999-04-13 2002-03-20 Nicox Sa Composti farmaceutici.
EP1189924B1 (en) * 1999-06-23 2004-08-18 Forbes Medi-Tech Inc. Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease
AU2001242130A1 (en) * 2000-03-07 2001-09-17 Forbes Medi-Tech Inc. Novel derivatives comprising phytosterols and/or phytostanols and alpha-lipoic and use thereof in treating or preventing cardiovascular disease, its underlying conditions and other disorders
CA2304906A1 (en) * 2000-04-07 2001-10-07 1411198 Ontario Limited 13-hode, a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia
DK1333838T3 (da) * 2000-10-25 2007-04-10 Forbes Medi Tech Inc Forbindelser, der omfatter en phytosterol- og/eller phytostanoldel og ascorbinsyre, og anvendelse deraf som vægtreguleringsmidler
US20030232797A1 (en) * 2002-06-06 2003-12-18 Forbes Medi-Tech Inc. Novel derivatives of androstane and androstene with ascorbic acid and use thereof in treating or preventing various conditions, diseases, and disorders
CN100348609C (zh) * 2002-06-19 2007-11-14 卡罗生物股份公司 治疗代谢紊乱的糖皮质激素受体配基
US20040133938A1 (en) * 2002-11-19 2004-07-08 Yinghui Dan Use of lipoic acid in plant culture media
US20040254357A1 (en) * 2002-12-19 2004-12-16 Zaloga Gary P. Fatty acid phenolic conjugates
CN1208052C (zh) * 2003-03-20 2005-06-29 上海家化联合股份有限公司 一种辅酶q10前体脂质体及其制备方法
JP5128799B2 (ja) * 2006-08-24 2013-01-23 株式会社アイ・ティー・オー チオクト酸誘導体を含有する生理活性組成物。
JP5412423B2 (ja) 2007-04-18 2014-02-12 コーナーストーン ファーマシューティカルズ，インコーポレーテッド リポ酸誘導体
NZ580973A (en) 2007-04-18 2011-10-28 Cornerstone Pharmaceuticals Inc Pharmaceutical formulations containing lipoic acid derivatives
US8263653B2 (en) 2007-04-18 2012-09-11 Cornerstone Pharmaceuticals, Inc. Pharmaceutical formulations containing lipoic acid derivatives
CA2704473C (en) * 2007-11-06 2016-10-04 Edison Pharmaceuticals, Inc. 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases
US7928067B2 (en) 2009-05-14 2011-04-19 Ischemix Llc Compositions and methods for treating ischemia and ischemia-reperfusion injury
CA2817362C (en) 2010-11-18 2018-10-23 Ischemix Llc Lipoyl compounds and their use for treating ischemic injury
AU2014398233B2 (en) 2014-06-19 2019-11-28 Rafael Pharmaceuticals, Inc. Pharmaceutical compounds
ES2819175T3 (es) 2014-06-19 2021-04-15 Rafael Pharmaceuticals Inc Compuestos farmacéuticos
CN104402962B (zh) * 2014-12-16 2016-01-13 吉林农业大学 硫辛酸环戊烷并多氢菲酯c及其提取方法和药物用途
WO2018200680A1 (en) 2017-04-25 2018-11-01 Ischemix Llc Compositions and methods for treating traumatic brain injury
CN118772089A (zh) * 2023-04-04 2024-10-15 华南理工大学 一种3-o-取代的l-抗坏血酸衍生物及其制备方法与应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3910888A (en) * 1971-08-04 1975-10-07 Medichemie A G Choleretically active esters and salts of bile acids
US4157984A (en) * 1977-06-08 1979-06-12 Z-L Limited Antioxidants, antioxidant compositions and methods of preparing and using same
EP0002423B1 (fr) * 1977-12-06 1981-10-14 Battelle Memorial Institute Procédé et machine pour le lavage et le blanchiment de matières textiles
US4232122A (en) * 1979-01-17 1980-11-04 Z-L Limited Partnership Antioxidants, antioxidant compositions and methods of preparing and using same
US4234577A (en) * 1979-03-19 1980-11-18 Z-L Limited Partnership Ergostadientriols, compositions containing same, and methods of preparing and using same
US4368264A (en) * 1979-03-19 1983-01-11 Z-L Limited Partnership Fermentation methods of preparing ergostadientriols
IL89850A0 (en) * 1988-04-25 1989-12-15 Takeda Chemical Industries Ltd Ester of ascorbic acid 2-phosphate
DE69314626T2 (de) * 1993-06-11 1998-05-14 Agfa Gevaert Nv Neuer Typ von modifizierter Gelatine und seine Verwendung in einem DTR-Material

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996038464A1 (en) * 1995-05-30 1996-12-05 Lehigh University Antimicrobial sterol conjugates
DE10028142A1 (de) * 2000-06-07 2001-12-20 Boehme Chem Fab Kg Chromgerbverfahren
DE10028142B4 (de) * 2000-06-07 2004-03-18 Dr. Th. Böhme KG Chem. Fabrik GmbH & Co Verfahren zum Pickeln und Chromgerben
DE102013226423A1 (de) 2013-12-18 2015-06-18 Henkel Ag & Co. Kgaa Haarbehandlungsmittel mit spezieller Konditioniermittelkombination
CN110407805A (zh) * 2019-07-09 2019-11-05 江苏第二师范学院（江苏省教育科学研究院） 硫辛酸醛类衍生物及其制备方法、应用

Also Published As

Publication number Publication date
HUT58757A (en) 1992-03-30
US5318987A (en) 1994-06-07
AU652928B2 (en) 1994-09-15
HU210905B (en) 1995-09-28
EP0436936A3 (enExample) 1994-04-27
NO910075D0 (no) 1991-01-08
PT96438A (pt) 1991-10-15
AU660248B2 (en) 1995-06-15
NZ236709A (en) 1992-11-25
IE910059A1 (en) 1991-07-17
EP0436936A2 (de) 1991-07-17
AU6189294A (en) 1994-07-21
HU910028D0 (en) 1991-08-28
PT96438B (pt) 1998-07-31
ZA91132B (en) 1991-10-30
NO910075L (no) 1991-07-10
US5508275A (en) 1996-04-16
KR910014365A (ko) 1991-08-31
AU6921791A (en) 1991-09-05
JPH04331284A (ja) 1992-11-19
CA2033755A1 (en) 1991-07-10

Similar Documents

Publication Publication Date Title
DE4000397A1 (de) Lipidselektive antioxidantien sowie deren herstellung und verwendung
DE69528291T2 (de) Nicht-beta oxidierbare fettsäureanaloge,deren verwendung als therapeutisch wirksame medikamente sowie deren herstellung
DE2414680C2 (de) Substituierte 2-Furancarbonsäuren und 2-Furancarbonsäureester, Verfahren zu ihrer Herstellung und Arzneimittel, die diese Verbindungen enthalten
DE69523654T2 (de) Verwendung von Ascorbyl-gamma-Linolenat und von Ascorbyl-dihomo-gamma-linolenat zur Behandlung von Asthma, Krebs, kardiovaskulären und inflammatorischen Erkrankungen
EP2842933A1 (de) Mischungen cannabinoider Verbindungen, deren Herstellung und Verwendung
EP0548261A1 (de) Neue sterolester und sterolphosphorverbindungen.
DE3146772C2 (de) Verwendung von Xanthogenatverbindungen, neue Xanthogenatverbindungen und ein Verfahren zu ihrer Herstellung
DE69512929T2 (de) Salze von aminoalkoholen und diese enthaltende pharmazeutische zusammensetzungen
AU2021225139A1 (en) Optic neuropathy treatment and reduction of steroid-induced oxidative stress with stabilized polyunsaturated substances
DE2831761C2 (de) 2,3- und 2,3,6-substituierte-4-Pyrone und deren Verwendung
DE69218196T2 (de) Cholesterinsenkende tocopherolanaloga
CH681152A5 (de) Neue biotenside und antitumorale ester und phosphatide mit vitamin-d- und vitamin-e-verbindungen, ihre herstellung und aufarbeitung zu spontan dispergierbaren konzentraten.
WO2002006261A1 (de) Tocotrienolchinon-zyklisierungsprodukte mit antihypercholesterin wirkung
EP0101898A1 (de) Anellierte 4H-1,4-Benzothiazine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE69016914T2 (de) Phospholipidderivate.
DE3125059A1 (de) Dioxybenzoletherderivate, diese enthaltende arzneimittel, verfahren zu ihrer herstellung und ihre verwendung
DE2843901A1 (de) Mittel, enthaltend all-e- oder 13-z-7, 8-dehydro-retinsaeure
EP0002219B1 (de) Arzneimittel mit schwefelhaltigen Estern und Verfahren zu ihrer Herstellung
DE2038836C3 (de) Arzneimittel
EP0966455B1 (de) Oxirancarbonsäuren für die behandlung von diabetes
EP0007347B1 (de) Lipidsenkende Alkylenglykolderivate und Verfahren zu ihrer Herstellung
DE19725799A1 (de) Neue Antiarteriosklerose-Mittel mit lipidsenkender Wirkung und Antiperoxidations-Aktivität
DE3432062A1 (de) Pyrazoldionderivate und ihre anwendung bei der bekaempfung von krankheiten
DE2753768A1 (de) Antiphologistisch wirkende arzneimittel
EP0100527A1 (de) 4H-1,4-Benzothiazine zur Verwendung als Arzneimittel

Legal Events

Date Code Title Description
8130 Withdrawal